Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind trial of VV119 capsules in acute schizophrenia
CTR20262596Phase 2Active
- Sponsor
- Vigonvita Life Sciences
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VV119 in schizophrenia, sponsored by Vigonvita Life Sciences. Started Aug 2026; status: active.
02
Drugs
VV119
03
Conditions
schizophrenia
Beyond the preview
Go deeper on CTR20262596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262596.